GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Gross Margin %

BRAIN Biotech AG (XTER:BNN) Gross Margin % : 53.59% (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. BRAIN Biotech AG's Gross Profit for the three months ended in Jun. 2024 was €7.07 Mil. BRAIN Biotech AG's Revenue for the three months ended in Jun. 2024 was €13.19 Mil. Therefore, BRAIN Biotech AG's Gross Margin % for the quarter that ended in Jun. 2024 was 53.59%.


The historical rank and industry rank for BRAIN Biotech AG's Gross Margin % or its related term are showing as below:

XTER:BNN' s Gross Margin % Range Over the Past 10 Years
Min: 48.02   Med: 54.44   Max: 56.19
Current: 55.93


During the past 9 years, the highest Gross Margin % of BRAIN Biotech AG was 56.19%. The lowest was 48.02%. And the median was 54.44%.

XTER:BNN's Gross Margin % is ranked better than
95.48% of 1504 companies
in the Chemicals industry
Industry Median: 22.12 vs XTER:BNN: 55.93

BRAIN Biotech AG had a gross margin of 53.59% for the quarter that ended in Jun. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for BRAIN Biotech AG was 1.50% per year.


BRAIN Biotech AG Gross Margin % Historical Data

The historical data trend for BRAIN Biotech AG's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG Gross Margin % Chart

BRAIN Biotech AG Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only 54.76 55.46 56.19 55.44 54.44

BRAIN Biotech AG Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.74 55.60 56.08 58.29 53.59

Competitive Comparison of BRAIN Biotech AG's Gross Margin %

For the Specialty Chemicals subindustry, BRAIN Biotech AG's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BRAIN Biotech AG's Gross Margin % Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Gross Margin % distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's Gross Margin % falls into.



BRAIN Biotech AG Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

BRAIN Biotech AG's Gross Margin for the fiscal year that ended in Sep. 2023 is calculated as

Gross Margin % (A: Sep. 2023 )=Gross Profit (A: Sep. 2023 ) / Revenue (A: Sep. 2023 )
=30.1 / 55.335
=(Revenue - Cost of Goods Sold) / Revenue
=(55.335 - 25.213) / 55.335
=54.44 %

BRAIN Biotech AG's Gross Margin for the quarter that ended in Jun. 2024 is calculated as


Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=7.1 / 13.19
=(Revenue - Cost of Goods Sold) / Revenue
=(13.19 - 6.122) / 13.19
=53.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


BRAIN Biotech AG  (XTER:BNN) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

BRAIN Biotech AG had a gross margin of 53.59% for the quarter that ended in Jun. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


BRAIN Biotech AG Gross Margin % Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BRAIN Biotech AG Business Description

Traded in Other Exchanges
Address
Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.
Executives
Dr. Michael Majerus Supervisory Board
Dr. Georg Kellinghusen Supervisory Board
Michael Schneiders Board of Directors
Adriaan Moelker Board of Directors
Lukas Linnig Board of Directors

BRAIN Biotech AG Headlines

No Headlines